Osteoporosis & Bone Density Treatment in Jammu: Diagnosis, Prevention & Expert Care

What Is Osteoporosis?

Osteoporosis — from the Greek meaning "porous bones" — is a skeletal disease characterised by reduced bone mineral density (BMD) and deterioration of bone microarchitecture. The result: bones that are fragile, brittle, and prone to fracture from forces that healthy bones would easily withstand — a minor fall, a cough, or even just bending over.

It is often called a "silent disease" because bone loss occurs without pain or obvious symptoms. Most patients do not know they have osteoporosis until a fracture occurs — often at the wrist, spine, or hip. A hip fracture in an older patient is not merely an injury; it carries significant mortality risk and often marks a permanent decline in independence and quality of life.

In India, the burden of osteoporosis is enormous — estimated to affect over 36 million women and rising numbers of men. In Jammu, Samba, Kathua, Udhampur, Bari Brahmana, and across J&K, many patients who experience fractures have never had their bone density evaluated — a missed opportunity for prevention that our specialists at Sedna Hospitals are working to change.

Osteopenia vs Osteoporosis

Osteopenia is the stage between normal bone density and osteoporosis — a "yellow warning zone" where intervention can prevent progression. It is defined as a T-score between -1.0 and -2.5 on DEXA scan. Osteoporosis is diagnosed at T-score -2.5 or below. Both conditions benefit from medical management — the approach differs by severity.

Causes and Risk Factors

Bone density peaks in early adulthood (around age 25–30) and gradually declines thereafter. The rate of decline is influenced by multiple factors:

Signs, Symptoms & Complications

Osteoporosis itself produces no symptoms — but its consequences are severe. The following are red flags and complications to be aware of:

Diagnosis — DEXA Scan and Beyond

Dual-Energy X-Ray Absorptiometry (DEXA Scan): The gold standard for bone density measurement. Painless, quick (15 minutes), and delivers minimal radiation. Measures bone density at the hip and lumbar spine, reporting a T-score compared to a reference young adult population. DEXA is recommended for: all women over 65; post-menopausal women under 65 with risk factors; men over 70; anyone with fragility fractures; patients on long-term steroid therapy.

FRAX Score: A validated tool that calculates 10-year fracture probability based on clinical risk factors with or without DEXA. Guides treatment decisions in patients where DEXA results are borderline. Blood Tests: Serum calcium, phosphate, vitamin D, PTH, bone-specific alkaline phosphatase, and thyroid function. These identify secondary causes of osteoporosis that are treatable — crucial before prescribing anti-osteoporosis medication. Vertebral Fracture Assessment (VFA): A lateral spine image taken during DEXA to identify silent vertebral fractures — found in up to 30% of post-menopausal women.

Treatment of Osteoporosis

Non-Pharmacological Foundation

Calcium and Vitamin D: The essential foundation — without adequate calcium and vitamin D, no other treatment works optimally. Adults require 1000–1200 mg calcium daily (diet first, supplement if needed) and 800–2000 IU vitamin D daily. In J&K, where vitamin D deficiency is prevalent, supplementation is particularly important. Regular monitoring of vitamin D levels guides dosing.

Exercise: Weight-bearing exercise (walking, dancing, stair climbing) and resistance training (weights, resistance bands) are proven to slow bone loss and reduce fall risk. At least 30 minutes most days. Balance exercises (yoga, tai chi) specifically reduce fall risk in older adults. Fall prevention: Practical home modifications — removing trip hazards, improving lighting, using non-slip mats, installing grab rails — combined with medication review (many medications increase fall risk) can prevent the fractures that osteoporosis makes dangerous.

Pharmacological Treatment

Bisphosphonates (First Line): Alendronate, risedronate, zoledronic acid — reduce osteoclast activity (bone resorption), stabilise bone density, and reduce fracture risk by 40–70%. Oral preparations taken weekly or monthly. Zoledronic acid is given as a once-yearly intravenous infusion — ideal for patients who cannot tolerate oral tablets. Denosumab: A monoclonal antibody given as a subcutaneous injection every 6 months. Highly effective — reduces vertebral fracture risk by 68%, hip fracture by 40%. Used when bisphosphonates are contraindicated or ineffective. Hormone Replacement Therapy (HRT): Estrogen is highly effective at preventing post-menopausal bone loss — see our HRT page for full details. Teriparatide: A bone-forming agent (parathyroid hormone analogue) for severe osteoporosis — stimulates new bone formation rather than just slowing resorption. Reserved for the most severe cases due to cost and requirement for daily injections.

Frequently Asked Questions